RecruitingNot ApplicableNCT04858880

Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.

Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy: a Randomized Phase III Study.

Sponsor

Lund University Hospital

Enrollment

374 participants

Start Date

Apr 9, 2021

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \<0.70 ng/ml) after prostatectomy.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a personalized approach to radiation therapy for men whose prostate cancer has returned after surgery (shown by a rising PSA blood level), using advanced imaging to guide where to direct the radiation. **You may be eligible if...** - You are 18 years or older and in good general health - You have had your prostate removed and your cancer was confirmed in the surgical specimen - Your lymph nodes were cancer-free at the time of surgery - Your PSA level is between 0.15 and 0.70 ng/mL (indicating a biochemical recurrence) - Your life expectancy is greater than 10 years **You may NOT be eligible if...** - Your cancer has spread to lymph nodes or distant organs - Your PSA is outside the required range Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiation to the prostate bed with or without addition of radiation of lymph node irradiation.

Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.